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http://www.biomedcentral.com/1471-244X/13/132STUDY PROTOCOL Open AccessInvestigating the efficacy of integrated cognitive
behavioral therapy for adult treatment seeking
substance use disorder patients with comorbid
ADHD: study protocol of a randomized controlled
trial
Katelijne van Emmerik–van Oortmerssen1,2,3,4*, Ellen Vedel1,2, Maarten W Koeter3, Kim de Bruijn1,2,
Jack J M Dekker1, Wim van den Brink3 and Robert A Schoevers4Abstract
Background: Attention deficit hyperactivity disorder (ADHD) frequently co-occurs with substance use disorders
(SUD). The combination of ADHD and SUD is associated with a negative prognosis of both SUD and ADHD.
Pharmacological treatments of comorbid ADHD in adult patients with SUD have not been very successful. Recent
studies show positive effects of cognitive behavioral therapy (CBT) in ADHD patients without SUD, but CBT has not
been studied in ADHD patients with comorbid SUD.
Methods/design: This paper presents the protocol of a randomized controlled trial to test the efficacy of an
integrated CBT protocol aimed at reducing SUD as well as ADHD symptoms in SUD patients with a comorbid
diagnosis of ADHD. The experimental group receives 15 CBT sessions directed at symptom reduction of SUD as
well as ADHD. The control group receives treatment as usual, i.e. 10 CBT sessions directed at symptom reduction of
SUD only. The primary outcome is the level of self-reported ADHD symptoms. Secondary outcomes include
measures of substance use, depression and anxiety, quality of life, health care consumption and neuropsychological
functions.
Discussion: This is the first randomized controlled trial to test the efficacy of an integrated CBT protocol for adult
SUD patients with a comorbid diagnosis of ADHD. The rationale for the trial, the design, and the strengths and
limitations of the study are discussed.
Trial registration: This trial is registered in www.clinicaltrials.gov as NCT01431235.
Keywords: ADHD, SUD, Cognitive behavioral therapy, Adult, Integrated treatmentBackground
Adult Attention Deficit Hyperactivity Disorder (ADHD) is
highly frequent in Substance Use Disorder (SUD) patients
[1,2]. SUD patients with comorbid ADHD start abusing
substances at a younger age, use more substances and are
hospitalized more often than SUD patients without* Correspondence: katelijne.van.oortmerssen@arkin.nl
1Arkin Mental Health Care and Addiction Treatment Center, Amsterdam, The
Netherlands
2Jellinek Substance Abuse Treatment Center, Amsterdam, The Netherlands
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use, distribution, and reproduction in any medADHD [3]. ADHD is also associated with higher relapse
rates after a SUD treatment for cocaine dependence [4]
and alcohol dependence [5]. This results in suboptimal
outcomes of SUD treatment in this population. At the
same time, treatment of ADHD is compromised in the
presence of SUD. Most ADHD treatment studies using
methylphenidate in SUD patients have shown that this
medication was not effective in reduction of ADHD symp-
toms [6-11], and only one randomized controlled trial
reported some decrease in self-reported ADHD symptoms
after methylphenidate treatment of ADHD in SUDlicensee BioMed Central Ltd. This is an Open Access article distributed under the
icense (http://creativecommons.org/licenses/by/2.0), which permits unrestricted
ium, provided the original work is properly cited.
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substance use outcomes. Similarly, atomoxetine was not
superior to placebo in an RCT among adolescents with
ADHD and SUD (mainly cannabis, alcohol and/or nico-
tine dependence) [13]. However, Wilens and colleagues
found a significant decrease of ADHD symptoms when
they compared atomoxetine with placebo in adult alcohol
dependent patients with ADHD [14]. Again, there was no
significant effect on alcohol use.
Other treatment options for ADHD such as cognitive
behavioral therapy (CBT) or EEG neurofeedback have
not been investigated yet in ADHD patients with a comor-
bid SUD. However, three recent randomized controlled
trials reported a positive effect of CBT in adult ADHD
patients without substance abuse [15-17]. In the study by
Safren et al. [15], 86 adult ADHD patients with residual
ADHD symptoms during medication treatment were ran-
domized to individual CBT or to relaxation as a control
condition. Assessments of ADHD symptoms by blinded
investigators took place at baseline, post-treatment, and
at 6 months and 12 months follow up. CBT resulted in
a significant greater reduction of ADHD symptoms than
relaxation therapy, both post-treatment and at 1 year
follow up. In another study, Solanto et al. [16] investigated
a meta-cognitive group therapy designed to improve time
management, organization and planning in adults with
ADHD. A total of 88 patients were stratified by medica-
tion use and randomized to the meta-cognitive therapy or
a supportive psychotherapy group. Meta-cognitive therapy
yielded significantly greater improvements in ADHD
symptoms (self-rated, observer-rated by partner or family
member, or rated by a blind evaluator) than supportive
therapy. Finally, in the study by Emilsson et al. [17], 54
adult ADHD patients who were already on medication
were randomized to a CBT based group program or to
treatment as usual. Medium to large treatment effect
sizes were found for evaluator-rated and self-rated
ADHD symptoms at the end of treatment, which in-
creased further at three months follow up. In addition,
comorbid problems such as depression and anxiety
symptoms improved at follow-up with large effect sizes.
The current study is designed to test the efficacy of an
integrated CBT protocol combining a standardized motiv-
ational interviewing and coping skills training program for
SUD with a CBT program for ADHD. The CBT program
for SUD is based on evidence-based CBT protocols ad-
dressing substance abuse [18,19] adapted for use in the
Netherlands [20,21], whereas the CBT program for ADHD
is a series of adapted sessions from the treatment manual
by Safren et al. [22,23]. This latter treatment manual was
chosen because it was the only available evidence-based
individual CBT protocol for ADHD at that moment.
Apart from ADHD outcomes, we are also interested
in the potential effects of this integrated treatment onsubstance use. According to the self-medication hypoth-
esis [24], substances are (also) used to alleviate distress
caused by psychiatric disorders; this implies that a reduc-
tion of symptoms of ADHD could lead to an additional re-
duction in substance use compared to regular CBT for
SUD. Since impulsivity is related to drug use [25], ADHD
treatment could also result in reduced substance use be-
cause of a decline of impulsivity symptoms. Finally, effects
on anxiety and depressive symptoms, quality of life and
cost-effectiveness of the integrated treatment protocol are
examined.
Aims of the trial
The aims of this trial are to test the acceptance, feasibility,
efficacy and cost-effectiveness of an individual integrated
CBT protocol for SUD patients with a comorbid diagnosis
of adult ADHD. The integrated CBT protocol aims to
address both SUD and ADHD.
The primary research question is:
1. Does adding a CBT program aimed at reducing
ADHD symptoms to a cognitive behavioral
treatment as usual for SUD (TAU), result in a
decrease of self-reported ADHD symptoms in adults
with SUD and comorbid adult ADHD compared to
TAU only at the end of treatment and at two
months follow-up?
Secondary research questions are:
1. Does adding a CBT program aimed at reducing
ADHD symptoms to TAU result in a greater
reduction of self-reported substance use in adults
with SUD and comorbid adult ADHD than TAU
only?
2. Does adding a CBT program aimed at reducing
ADHD symptoms to TAU result in a greater
decrease of self-reported depression and anxiety and
a greater increase in quality of life than TAU only?
3. Does adding a CBT program aimed at reducing
ADHD symptoms to TAU result in a greater
improvement in neuropsychological functions than
TAU only?
4. What are the comparative costs per gained quality
adjusted life year (QALY) for the integrated CBT
protocol and TAU only?
5. Are baseline characteristics (e.g. performance on
neuropsychological tasks) predictive of treatment
response to either TAU or integrated CBT (patient-
treatment matching)?
We hypothesize that patients in the integrated treatment
condition will achieve stronger reductions in ADHD
symptoms than patients in the TAU only condition at the
van Emmerik–van Oortmerssen et al. BMC Psychiatry 2013, 13:132 Page 3 of 11
http://www.biomedcentral.com/1471-244X/13/132end of treatment and at 2 months follow-up. Moreover,
we expect participants in the integrated treatment condi-
tion to have lower scores on self-reported substance use,
depression and anxiety and higher scores on quality of life
than participants in the TAU only condition at the same
time points. We also expect the integrated CBT protocol
to result in greater improvements in performance on
neuropsychological tasks, and we expect the integrated
CBT protocol to have a higher cost-utility than TAU only.
At this moment, we have no explicit hypothesis about the
baseline characteristics that might be predictive of treat-
ment response in terms of a decrease of ADHD symptoms





Participants are (self )referrals seeking treatment for their
substance use problems at the Jellinek, a large addiction
treatment center in Amsterdam, the Netherlands. To be
eligible for the study, patients have to meet the following
inclusion criteria: after intake allocated to outpatient
treatment unit, aged 18–65 years, full command over
the Dutch language, current DSM-IV diagnosis of any
substance use disorder other than nicotine dependence
only, and a comorbid DSM-IV diagnosis of ADHD with
persisting symptoms meeting diagnostic criteria in adult-
hood. Patients with pathological gambling and other be-
havioral addictions are not included.
Exclusion criteria
Patients with severe neurological (e.g. dementia, Parkinson’s
disease) or psychiatric disorders (e.g. psychosis, bipolar
disorder) requiring medication, are excluded from the
study. Patients with a borderline personality disorder are
also excluded and referred to adequate treatment for this
condition. Patients currently using ADHD medication (e.g.
methylphenidate) are allowed to participate provided that
they are on a stable dose and no medication changes are
planned for the duration of the trial.
Design and procedure
Recruitment and consent
During the standardized intake and treatment allocation
procedure at the Jellinek, patients are screened for
ADHD. Screen positive patients are invited for a semi-
structured diagnostic interview with a specially trained
psychologist to assess the presence of a DSM-IV diagno-
sis of adult ADHD. If ADHD, persisting in adulthood, is
diagnosed, the patient is informed about the possible
treatment options and receives oral and written informa-
tion on the treatment study. If the patient is interested
in participation, he or she is contacted by telephone byone of the investigators for further information. If the
patient wants to participate in the study, informed con-
sent is signed during the next visit. In the current study,
no (additional) ADHD medication is provided.
Randomization and treatment allocation
Patients are randomized to receive either Treatment As
Usual directed at the treatment of SUD (TAU only) or
TAU plus CBT sessions aimed at reducing ADHD symp-
toms (integrated treatment condition). Treatment alloca-
tion is performed randomly by online application of a
biased-coin randomization (minimization). In this way,
we aim to ensure that trial arms are balanced with re-
spect to three baseline characteristics: gender, use of
ADHD medication (yes/no), and type of SUD diagnosis
(alcohol only versus drugs). Neither patients nor therapists
or investigators are blinded for the treatment allocation.
Procedure
Figure 1 provides an overview of the trial flow. Diagnostic
assessment of SUD (CIDI), and screening and diagnostic
assessment of ADHD (ASRS and CAADID; description
of all three measures see below) take place at t-1. After
informed consent and baseline assessment (t0), all partici-
pating patients start with phase 1 of the SUD treatment
(four weekly sessions). During this treatment phase pa-
tients are motivated and stimulated to reach full abstin-
ence in order to validate the ADHD diagnosis, i.e. a
diagnosis not distorted by the presence of intoxication
or withdrawal symptoms. The second ADHD assess-
ment (CAADID), after the fourth session, is performed
by another investigator. If the original ADHD diagnosis
is confirmed, randomization takes place (t1). Following
randomization, patients in the TAU only condition re-
ceive another six standard SUD treatment sessions in
the course of the next three months (resulting in a total
offer of 10 CBT sessions directed at treatment of SUD),
whereas patients in the integrated treatment condition
receive another 11 treatment sessions on both SUD
treatment and ADHD treatment in the next three
months (resulting in a total offer of 15 CBT sessions di-
rected at treatment of both SUD and ADHD). At the end
of treatment, all participants are assessed again (t2). A fol-
low up assessment (t3) is performed two months after the
last treatment session. Finally, participants in the TAU
only condition are offered five ADHD treatment sessions
after the follow up assessment (two months after end of
treatment) as a compassionate treatment offer.
Treatment protocols
Participants in the TAU only condition receive outpatient
substance abuse treatment using a treatment program for
SUD that is implemented nationally in the Netherlands
[20,21]. The program is based on the Motivational
- Recruitment of SUD patients with ADHD
- Informed consent
- to baseline measure
Phase 1: four sessions of SUD
treatment (4 weeks)
t2 (outcome measure)
Trial arm 1: experimental condition:
Integrated treatment protocol (ADHD and 
SUD treatment).
11 sessions in 3 months
t2 (outcome measure)
Trial arm 2: control condition:
TAU only (SUD treatment)
6 sessions in 3 months
Randomisation (t1)
Re-evaluation of diagnosis ADHD (t1)
t3 (follow up measure) t3 (follow up measure)
Analysis Analysis
3 months after t1
2 months after t2
Figure 1 Trial flowchart.
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Coping skills training manual used in project MATCH
[18,19] and consists of 10 sessions of motivational
interviewing, skills training and relapse prevention. In the
first session, advantages and disadvantages of substance
use are discussed. In the current study, the first session
is also used to explain that substance use can cause
symptoms that mimic ADHD symptoms. With motiv-
ational interviewing techniques, patients are motivated
for abstinence in order to assess the effect of abstinence
on their ADHD symptoms. As soon as a patient is moti-
vated to become abstinent, or at least reduce substance
use, procedures and self control measures on how to
achieve this goal are discussed. Also risk factors for
using substances (e.g. meeting certain persons, being in
certain places or having certain feelings) are identified.
These first four sessions (treatment phase 1) are the
same for all participating patients, i.e. independent of
the treatment condition after randomization. Subse-
quently, the diagnostic assessment of ADHD is re-
peated, and if the ADHD diagnosis is confirmed,
randomization takes place. The remaining six sessions
in the TAU only condition are used for a range of SUD
treatment interventions. A functional analysis of thesubstance abusing behavior is made, strategies are
trained to cope with craving, dealing with lapses and
preventing relapse, and social refusal skills are offered.
In the ninth session the patient can repeat one of the
coping skills or choose one of several optional topics,
depending on the specific needs of the patient. The
treatment is concluded with an evaluation.
Participants in the experimental treatment condition
receive an integrated treatment for SUD and ADHD, com-
bining the main elements of the CBT program for SUD
with CBT interventions for ADHD from the ‘Mastering
your adult ADHD’ program developed by Safren et al.
[22,23]. The original treatment program by Safren et al.
[22] focuses on the training of coping skills and on
symptom management strategies. It consists of 12 ses-
sions, divided into three core modules, two optional
modules, and a closing session. The first module (four
sessions) focuses on psycho-education about ADHD
and several organization and planning skills, such as
using a calendar and task list system, problem solving
by generating alternatives and picking the best solution,
and breaking down complex or overwhelming tasks into
smaller steps. The second module (two sessions) focuses
on reducing distractibility by removing sources of
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tions versus acting on them. The third module (three
sessions) involves cognitive restructuring and adaptive
thinking. Optional modules can be used to tackle procras-
tination and to involve a family member for support. The
final session is used for evaluation and relapse prevention.
For the integrated treatment condition, the ADHD
treatment program and the CBT program for the treat-
ment of substance use disorders were integrated in the
following way. We adapted the original ADHD treatment
into a more condensed version, in which the core ele-
ments of planning and organization skills are presented
to the patients in five sessions. In another six sessions
from the CBT program directed at the treatment of
SUD, 15 minutes are used each session to discuss home-
work assignments on the ADHD themes and to evaluate
the learned skills. Similarly, in the five ADHD sessions,
15 minutes are used to discuss homework assignments
on SUD themes. In this way, attention to the training of
planning and organizational skills is given in 11 sessions
in total. The contrast between the two approaches thus
concerns five extra sessions ‘net-time’ on ADHD related
issues in the integrated treatment protocol, plus the fact
that ADHD symptoms are at least briefly discussed in
11 sessions. Sessions are planned weekly on a fixed time
and day as much as possible. The outlines of the controlTable 1 Treatment programs
Treatment as Usual (TAU) only
Session 1 Introduction, advantages and disadvantages of substance use,
effect of substance use on mental problems, enhancing motiva
to become abstinent
Session 2 Treatment goals and treatment plan
Session 3 Self control measures
Session 4 Risk situations
Session 5 Analysis of functional elements in substance use
Session 6 Dealing with craving
Session 7 Relapse and relapse prevention
Session 8 Social pressure
Session 9 Optional theme: one of earlier themes can be repeated, or one







Session 15condition (TAU only) and integrated treatment protocol
are described in Table 1.Therapists
Both TAU only and integrated treatment sessions are
delivered by therapists who received formal training and
supervision in delivering protocolized CBT for SUD and
have extensive experience of more than eight years. All
therapists received four hours additional training for the
CBT interventions targeting ADHD symptoms. Weekly
supervision of both integrated treatments and TAU only
by an experienced staff member (EV) is provided for the
duration of the trial.
Measurements
With the exception of some self-report questionnaires,
most assessments are conducted in face-to-face contacts.
The following instruments are used (see also Table 2):
Selection and diagnostic measurements
1. The DSM-IV diagnosis of SUD is made using a
Dutch questionnaire based on the Composite
International Diagnostic Interview (CIDI vs 2.1)
[26].Integrated treatment protocol
tion
Introduction, advantages and disadvantages of substance use,
effect of substance use on mental problems, enhancing motivation
to become abstinent
Treatment goals and treatment plan
Self control measures
Risk situations
ADHD: introduction of a cognitive model of ADHD, introduction of
calendar and task list in notebook
Analysis of functional elements in substance use (similar to session
5 in TAU)
ADHD: problem solving




Relapse and relapse prevention (Similar to session 7 in TAU)
ADHD: mood problems
Social pressure (similar to session 8 in TAU)
ADHD: organizing papers
Optional theme: one of earlier themes can be repeated, or one of
the themes ‘changing of thoughts’ or ‘dealing with emotions’ can
be explored. (similar to session 9 in TAU)
Evaluation (Similar to session 10 in TAU)
Table 2 Measurement instruments














SCID II Borderline If MSI-BPD > 6
ADHD rating scale • • •
TLFB • • • •
BDI, BAI • • •
EQ-5D • • •
TIC-P • • •
Computerized tests: BART, Stroop and
Tower of London
• • •
Urine test and breath analysis • • •
Abbreviations: CIDI, Composite International Diagnostic Interview; ASRS, Adult ADHD Self Report Scale; CAADID, Conners’ Adult ADHD Diagnostic Interview for
DSM-IV; MSI-BPD, McLean Screening Instrument for Borderline Personality Disorder; SCID II, Structured Clinical Interview for DSM-IV Axis II; TLFB, Time Line Follow
Back; BDI, Beck Depression. Inventory; BAI, Beck Anxiety Inventory; EQ-5D, a measure of health status from the EuroQol Group; TIC-P, questionnaire for costs
associated with psychiatric illness (in Dutch); BART, Balloon Analogue Risk Task; Stroop, Stroop Color-Word task; TOL, Tower of London.
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with the first six items of the Adult ADHD Self-
Report Scale (ASRS v1.1) [27,28].
3. The DSM-IV diagnosis of ADHD is based on a semi-
structured interview, the Conners’Adult ADHD
Diagnostic Interview for DSM-IV (CAADID) [29].
4. Screening for the presence of a Borderline
Personality Disorder is performed with the McLean
Screening Instrument for Borderline Personality
Disorder (MSI-BPD) [30].
5. In case of a score of seven or higher on the MSI-
BPD, diagnostic evaluation of a Borderline
Personality Disorder is performed with the
corresponding module of the Structured Interview
for DSM-IV Axis II (SCID II) [31,32].
The first two instruments were already implemented
on the research site because they were used in an inter-
national study on the prevalence of ADHD in adults
seeking treatment for substance use disorders (IASP
study: International ADHD in Substance use disorder
Prevalence study) [33], developed and executed by the
International Collaboration on ADHD and Substance
Abuse (ICASA), in which the treatment centre of the
current study participated.
The ASRS has been validated for use in the general
adult population [27] and some small validity studies are
available for SUD patients [34-36]. Meanwhile, the IASP
study has collected data on the validity of this instru-
ment in a SUD population showing adequate sensitivity
and specificity even in patients still actively using sub-
stances [37].The CAADID consists of two parts. In the first part of
the CAADID, information is obtained on the develop-
mental history of the patient. This part can be filled out
by the patient, preferably with the help of parents, before
coming to the diagnostic appointment. In the second
part of the CAADID, the presence of all ADHD symptoms
is checked for both childhood and adulthood. Although it
is generally recommended to include an interview with a
family member in the diagnostic procedure in order to ob-
tain information on childhood behaviors, we chose not to
include such an interview in our diagnostic procedure.
This choice was made because of logistic reasons and also
because we encounter a lot of patients who have lost con-
tact with their relatives due to their substance use dis-
order. Moreover, the study by Murphy and Schachar
showed that adult patients can give a true account of both
childhood and current symptoms of ADHD [38]. Another
complexity of the diagnostic procedure in this patient
population is the fact that we perform the diagnostic
assessment of ADHD at a moment in time (during the in-
take phase) where most patients are still actively abusing
substances. This may bias the results of the assessment,
but for early detection and effective treatment allocation it
is necessary to perform the diagnostic assessment in an
early stage. In order to obtain a reliable and valid ADHD
assessment, we chose to repeat the diagnostic interview
for ADHD (CAADID) after four sessions of SUD treat-
ment. We expect that most patients will have reached ab-
stinence or achieved a substantial reduction of substance
use by that time and that intoxication and withdrawal
symptoms will no longer influence the assessment. If a
diagnosis of ADHD is not confirmed at that moment, the
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ond treatment phase of the study and receives regular
TAU for SUD.
The MSI-BPD yielded both good sensitivity (0.81) and
good specificity (0.85) in a non-substance abusing popu-
lation when using a cut-off value of 7 [30]. In case of a
positive screening result on the MSI-BPD, diagnostic
evaluation of Borderline Personality Disorder is
performed. Patients with a diagnosis of Borderline Per-
sonality Disorder are excluded from the study and allo-
cated to adequate treatment.
Outcome measures
1. The ADHD rating scale is used as the measure for
severity of ADHD symptoms [39], Dutch version
[40,41]. In the Dutch version, the ADHD rating
scale is a 23 item self-report questionnaire in which
each item is scored on a 4-point scale ranging from
0 to 3.
2. The Time Line Follow Back (TLFB) [42-44] is used
as a self-report measure for alcohol consumption
and other substance use. In this study, it is used to
assess alcohol and drug use in the past two months.
From this questionnaire, several scores can be
derived; in the statistical analyses we use a combined
measure of percentage days of excessive use in the
past two months for the primary drug of abuse,
defined as at least six standard units of alcoholic
beverages for men per day, at least four standard
units of alcoholic beverages for women (in the case
of alcohol as the primary drug of abuse) per day,
more than one joint (in the case of cannabis as the
primary drug of abuse) per day, or any use of other
illicit drugs.
3. The Beck Depression Inventory (BDI) [45] is used as
self-report questionnaire to measure the presence
and severity of current depressive symptoms. It
consists of 21 items in which each item is scored on
a 4-point scale ranging from 0 to 3. Similarly, the
Beck Anxiety Inventory (BAI) [46] is used to
measure the presence and severity of anxiety
symptoms. The BAI consists of 21 items scored on a
4-point scale ranging from 0 to 3.
4. The EQ-5D is a five-dimensional instrument for
measuring quality of life [47,48]. The EQ-5D has
shown to be valid in heroin dependent and in
alcohol dependent patients [49,50]. It is used for
cost-utility analyses.
5. The TIC-P is a questionnaire measuring the costs
associated with psychiatric illness [51]. It has been
used in many studies about patients with mental
disorders (including schizophrenia, depression and
ADHD) to estimate direct medical costs and costsdue to production losses in order to perform cost-
utility and cost-benefit analyses [52-56].
6. Computerized neuropsychological tests are
performed to objectively assess (changes in) ADHD
associated neuropsychological functions.
a. The Balloon Analogue Risk Task (BART) [57]
provides information on risk taking behavior.
This task can give information on subtypes of
ADHD patients within a SUD population,
differentiating between patients with high and
low scores on risk taking behavior.
b. The Stroop Color-Word task [58-60] provides
information on interference control. Patients with
ADHD have repeatedly been reported to be
impaired on this task [61,62]. Atomoxetine has
been reported to improve the function on this
task in adult patients with ADHD [63]. It is
currently unknown if a planning and organization
intervention can improve the performance on
this task in ADHD patients.
c. The Tower of London task [64] is performed to
measure planning ability. Patients with ADHD are
reported to have impaired functions of planning.
Methylphenidate can improve this function in
adult ADHD patients [65] and it is interesting to
learn if a planning and organization intervention
can improve the performance on this task too.
7. Results of urine samples and breath analyses are
used to provide additional, objective information on
substance use.
Primary and secondary outcome measures
The primary outcome measure is the difference in the se-
verity of ADHD symptoms according to the ADHD rating
scale [40] between the integrated treatment condition and
the TAU only condition at the end of the treatment (t1).
Key secondary outcome measures are the difference in
the severity of ADHD symptoms between the two condi-
tions at follow up two months after end of treatment
(t2), and the difference of percentage of treatment
responders (defined as a reduction of at least 30% of
ADHD symptoms [15,16,66,67]) between TAU only and
the integrated treatment condition at end of treatment
and at follow up. The difference of TLFB scores between
the two conditions at end of treatment and at follow up
is another key secondary outcome measure.
Other secondary outcome measures are the differ-
ences in scores on the BDI, BAI, EQ-5D, TIC-P, Stroop
task and Tower of London task at end of treatment and
at follow up.
Statistical analysis
Data will be analyzed according to the intention-to-treat
principle. The effect of the integrated treatment in terms
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generalized linear mixed model regression analysis
(GLMM) with (Ytj-Yt1), j = 2,3 as dependent variable vector;
treatment condition, time and the treatment condition
by time interaction as predictor, and Yt1 (i.e. baseline
value) as covariate. This model assumes missing at ran-
dom (MAR), which adjusts the effect estimates for po-
tential bias due to differential loss to follow-up. GLMM
will also be used for the analysis of the secondary out-
come variables, except the binary treatment responder
outcome, for which a Generalized Estimating Equation
model (GEE) will be used.
Costs will be calculated using standard costs for
economic evaluations in health care [68]. The cost-
effectiveness ratio is defined as the ratio of incremental
mean costs and the incremental mean effect of the inte-
grated treatment versus TAU only. Bootstrapping will
be used to calculate the confidence interval for this ra-
tio. In addition, a cost-utility analysis will be performed
with data of the costs and quality of life of participants
in both treatment conditions.
All analyses will be performed with SPSS 20 (SPSS Inc,
Chicago, IL, USA).Sample size
The primary outcome is the difference in the severity of
ADHD symptoms according to the ADHD rating scale
[40] between the experimental condition (integrated treat-
ment) and the control condition (TAU only) at the end of
the treatment (t2) using an ITTanalysis and GLMM to ac-
count for missing values. In the study by Safren et al. [15]
among ADHD patients without SUD, the between group
standardized effect size (d) in terms of ADHD symptom
scores was 0.60. We expect a somewhat smaller effect size
because the population of patients with ADHD and SUD
has potentially more complex problems, the intervention
in the current study is a shorter version than the original
one, and the contrast between the two conditions (inte-
grated treatment and TAU) is smaller, because CBT is
used in both conditions. On the other hand, time to follow
up is shorter in the current study. Therefore, we estimate
the effect size at d = 0.5 (medium effect). Based on a two-
sided alpha = 0.05 and power = 0.80, 65 patients are
needed in each condition. In order to adjust for loss of
power due to an anticipated drop out of 15%, 150 partici-
pants will be included.Ethical review and trial registration
This RCT has been reviewed and approved by the ethics
committee of the Academic Medical Centre in Amsterdam
(number 10–130). It is registered in www.clinicaltrials.gov
as NCT01431235.Discussion
To the best of our knowledge, this is the first random-
ized controlled trial to test the efficacy of an integrated
CBT protocol aimed at reducing SUD as well as ADHD
symptoms in a SUD population with comorbid adult
ADHD. In the absence of effective pharmacological
treatment options for ADHD in these patients, it is vital
that other treatment options such as CBT are tested.
Recent results of CBT interventions in ADHD patients,
as shown by Safren et al. [15], Solanto et al. [16] and
Emilsson et al. [17], are quite encouraging and we hope
to find positive results in this dual disorder patient
population as well by adding a CBT program directed at
ADHD symptoms to an existing evidence-based CBT
directed at SUD treatment.
In the regular practice of our SUD treatment centre,
abstinence of substances is pursued first, and referral to
an ADHD outpatient clinic is generally effectuated at a
later stage. However, ADHD patients are often not iden-
tified in this population whereas ADHD symptoms often
interfere with SUD treatment, for example in the most
elemental way by forgetting appointments with thera-
pists due to a lack of organization skills. This results in
less optimal SUD treatment outcomes and very low
numbers of patients actually receiving adequate ADHD
treatment. We hypothesize that integrating treatment of
ADHD symptoms with SUD treatment will show a bet-
ter outcome. Two major challenges in both treatment
and research of these patients with complex disorders
are the tendency to relapse into substance use and the
problems with planning and treatment adherence. In
fact, we envisage that the greatest challenge of this study
will be to prevent participants from dropping out of the
study. We expect that SUD patients with comorbid
ADHD will show higher levels of impulsivity and treat-
ment drop-out, which requires a creative and persistent
approach from both therapists and investigators. We
addressed this by giving special attention to the format
of the treatment: we chose for an individual version in
order to allow for optimal flexibility of patient inflow
and to avoid waiting lists. We also try to schedule the
appointments in both treatment conditions at a fixed
day and time to minimize the chance of forgetting ap-
pointments, and patients are reminded of their ap-
pointments by text messages sent the day before the
appointment. Furthermore, in our power calculation
we allowed for relatively high numbers of drop outs in
phase 1 of the treatment. Patients who drop out of
treatment in phase 2 of the treatment are still
approached for outcome and follow up assessments; if
patients are unwilling to come to the clinic for this
purpose, a shortened version consisting of the ADHD
rating scale and the Time Line Follow Back is adminis-
tered by telephone in order to collect at least the most
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We also expect that relapse into substance use, or in-
ability to become abstinent, will be a common problem
in both treatment conditions. Although treatments are
aimed at full abstinence, relapse and continued sub-
stance use are no reason to end the treatment, but they
will require therapists to use the treatment protocol in
a flexible way. This can lead to diminished protocol
adherence, but on the other hand enhances ecological
validity of the study.
In this first trial, information is collected on acceptance,
feasibility, efficacy and cost-effectiveness of the integrated
treatment program compared to TAU only. It should be
noted, however, that we adapted the original adult
ADHD treatment program of Safren et al. [22,23] to a
shorter version that could be closely integrated with the
CBT treatment directed at reduction of SUD symptoms.
In this shorter version of the Safren et al. protocol, the
core skills of planning and organization, reducing dis-
tractibility, and coping with mood problems, are clearly
present but they are offered in a tighter time frame and
integrated with the existing treatment program for SUD
that partly overlaps with some of these skills. However,
several items from the original Safren et al. protocol are
removed, for example the part on gauging your personal
attention span. The part on cognitive restructuring is
shortened, but in the SUD treatment sessions ample at-
tention is given to this theme as well. In the integrated
treatment condition, all sessions after randomization
(sessions 5–15) are used to (also) evaluate ADHD skills.
Overall, we believe that ADHD problems therefore re-
ceive ample attention in the integrated treatment. The
result of our adaptations is a condensed version of the
original CBT program for adult ADHD, still containing
the core elements and covering the content of (a part of)
11 therapy sessions.
Patients who are already on a stable dose of ADHD
medication at study entry, can participate in the study,
but new medication is not provided to the participants.
As efficacy of stimulants and other ADHD medication
has not been shown in randomized trials yet, the efficacy
of the current medication options is at least controversial.
If patients want to start ADHD medication, they have
several options: they can be included in the study if they
agree to postpone medication use until the end of study
(i.e. after the two months follow-up period) or they can
refuse participation in this study and be referred to an
ADHD treatment centre where medication can be pre-
scribed. Of course, patients can withdraw from partici-
pation any time during the study and therapists can
always refer a participant for a medication consult if
they feel that medication is necessary.
An important difference between the current study
and the study by Safren et al. [15] concerns the design ofthe control condition. As we want to know whether the
integrated treatment has advantages over the treatment
as usual, it is vital that we preserve the CBT program for
SUD (TAU only) as the control condition in our design.
This reduces the contrast between the two conditions,
because in both conditions patients receive CBT. This is
essentially different from a relaxation therapy used by
Safren et al. [15] or support group (used by Solanto
et al. [16]) as control condition, and reduces the prob-
ability of finding a positive result. At the same time, this
makes the current design highly relevant for daily clinical
practice as the difference between the two conditions in
our study is made only by the number of sessions and the
specific content of the CBT. Furthermore, the CBT pro-
gram for SUD is the standard treatment of SUD in the
Netherlands, and the merits of additional treatment com-
ponents should be weighed against the results of this TAU
program.
The unequal amount of therapy sessions that partici-
pants in the integrated treatment condition and in the
TAU only condition receive is a limitation as well. Al-
though we are aware that conclusions on the effective-
ness of the CBT interventions for ADHD are limited
because any effects, should they occur, can be attributed
to having had more therapy time and attention in general,
we decided in favor of this design as it is the first study on
this issue in this patient population. Furthermore, the
difference in time spent in therapy between the two condi-
tions is relatively limited and may in reality even be
smaller since not all patients will attend all sessions. In this
first study we want to explore whether a combination of a
little extra time with a more specific ADHD treatment is
effective at all and whether this is cost-effective.
Another limitation of our design is the fact that assessors
are not blinded for treatment allocation (and of course
patients and therapists are not blinded either), because
of logistic reasons. Again, we realize that this may intro-
duce (information) bias. However, the presence of ob-
jective measures such as neuropsychological tests and
biological markers of substance use will allow us to ex-
plore whether such bias really occurred and how such
bias may have influenced the results.
Despite these challenges and limitations, we think that
this study provides a first important step towards develop-
ing a tailored integrated treatment protocol for patients
with SUD and comorbid ADHD.
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